Ophthalmology Times: Orasis Pharmaceuticals' $78 Million Financing for Qlosi Eye Drop Launch
Ophthalmology Times: Overview of Qlosi's Launch
Orasis Pharmaceuticals has announced the completion of a *$78 million financing* to support the commercial launch of *pilocarpine hydrochloride ophthalmic solution* 0.4% (Qlosi). This *novel corrective eye drop* is specifically aimed at the treatment of presbyopia in adults.
Key Features of Qlosi
- The solution is a **prescription eye drop** that can be used daily or up to twice daily as needed.
- It demonstrates *efficacy* 20 minutes after administration, lasting up to **8 hours**, measured on day 15.
- With a *preservative-free* formulation, Qlosi is crafted to balance efficacy, *safety*, and comfort.
Investor Insights and Future Prospects
According to the company, the *Series D financing* involved a *$68 million equity* component led by **Arboretum Ventures** and **Johnson & Johnson Innovation** – JJDC, Inc., along with collaborations from **Catalio Capital Management**, **Freepoint Capital Group**, and several returning investors.
Elad Kedar, CEO of Orasis, stated, “This significant funding enables us to successfully launch Qlosi, presenting the eye care community with a *near-vision solution* that balances efficacy and *tolerability*.”
Paul McCreadie, managing partner at Arboretum Ventures, remarked, “We have high confidence in the Orasis team to successfully launch Qlosi and positively impact patients’ near vision.”
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.